cardizem
| Product dosage: 120mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.44 | $43.35 (0%) | 🛒 Add to cart |
| 60 | $1.08 | $86.69 $64.52 (26%) | 🛒 Add to cart |
| 90 | $0.96 | $130.04 $86.69 (33%) | 🛒 Add to cart |
| 120 | $0.90 | $173.39 $107.86 (38%) | 🛒 Add to cart |
| 180 | $0.84 | $260.08 $151.21 (42%) | 🛒 Add to cart |
| 270 | $0.80 | $390.13 $215.73 (45%) | 🛒 Add to cart |
| 360 | $0.78
Best per pill | $520.17 $280.25 (46%) | 🛒 Add to cart |
| Product dosage: 180mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.25 | $67.54 (0%) | 🛒 Add to cart |
| 60 | $1.44 | $135.08 $86.69 (36%) | 🛒 Add to cart |
| 90 | $1.18 | $202.62 $105.85 (48%) | 🛒 Add to cart |
| 120 | $1.04 | $270.16 $125.00 (54%) | 🛒 Add to cart |
| 180 | $0.91 | $405.25 $163.31 (60%) | 🛒 Add to cart |
| 270 | $0.81 | $607.87 $218.75 (64%) | 🛒 Add to cart |
| 360 | $0.77
Best per pill | $810.49 $276.21 (66%) | 🛒 Add to cart |
Cardizem, known generically as diltiazem, is a calcium channel blocker primarily prescribed for managing cardiovascular conditions such as hypertension, chronic stable angina, and certain arrhythmias like atrial fibrillation. It functions by inhibiting calcium ion influx during cardiac and vascular smooth muscle depolarization, leading to reduced peripheral vascular resistance and myocardial oxygen demand. Available in various formulations including immediate-release tablets, extended-release capsules, and intravenous injections, Cardizem is a cornerstone therapy in cardiology due to its efficacy and relatively favorable side effect profile. This monograph provides a comprehensive, evidence-based overview for healthcare professionals and informed patients.
1. Introduction: What is Cardizem? Its Role in Modern Medicine
Cardizem is a prescription medication belonging to the benzothiazepine class of calcium channel blockers. It is fundamentally used to treat high blood pressure, chest pain associated with coronary artery disease, and specific heart rhythm disorders. Since its approval, Cardizem has become integral in cardiovascular pharmacotherapy, offering a balance between effectiveness and tolerability. Its role extends to preventing myocardial infarction and stroke in high-risk patients, underscoring its importance in preventive cardiology. Understanding what Cardizem is used for involves recognizing its dual action on the heart and blood vessels, making it versatile for various patient profiles.
2. Key Components and Bioavailability Cardizem
The active pharmaceutical ingredient in Cardizem is diltiazem hydrochloride, available in several salt forms to optimize stability and absorption. Formulations include immediate-release (IR) tablets, extended-release (ER) capsules (e.g., Cardizem CD, LA), and injectable solutions for acute settings. Bioavailability varies significantly: IR tablets have approximately 40% bioavailability due to first-pass metabolism, while ER forms are designed for sustained release, maintaining steady plasma concentrations over 24 hours. The inclusion of specific excipients like hydroxypropyl methylcellulose in ER versions controls dissolution rates, enhancing patient compliance by reducing dosing frequency. This pharmacokinetic profile is crucial for tailoring therapy to individual needs, especially in chronic conditions requiring long-term management.
3. Mechanism of Action Cardizem: Scientific Substantiation
Cardizem works by selectively blocking L-type calcium channels in vascular smooth muscle and cardiac cells. This inhibition prevents calcium ions from entering cells during action potentials, leading to vasodilation of coronary and peripheral arteries and reduced heart rate and contractility. In simpler terms, it relaxes blood vessels to lower blood pressure and decreases the heart’s workload, which alleviates angina symptoms. Electrophysiologically, diltiazem prolongs AV node refractory periods, making it effective for rate control in supraventricular tachycardias. Research, including studies in the Journal of Cardiovascular Pharmacology, confirms that this mechanism reduces myocardial ischemia and improves exercise tolerance, forming a solid scientific basis for its clinical use.
4. Indications for Use: What is Cardizem Effective For?
Cardizem for Hypertension
Cardizem is first-line for essential hypertension, particularly in patients with comorbid angina or diabetes. Clinical trials, such as those published in Hypertension, demonstrate significant reductions in systolic and diastolic blood pressure, with ER formulations providing 24-hour control.
Cardizem for Chronic Stable Angina
By reducing afterload and heart rate, Cardizem decreases angina frequency and increases exercise capacity. It is often combined with nitrates or beta-blockers, though caution is needed to avoid excessive bradycardia.
Cardizem for Atrial Fibrillation and Flutter
Used for ventricular rate control, Cardizem IV is effective in acute settings, while oral forms maintain rate stability long-term. Studies in Circulation show rapid onset and efficacy in restoring hemodynamic stability.
Cardizem for Raynaud’s Phenomenon
Off-label, it improves peripheral blood flow by vasodilation, reducing the frequency and severity of vasospastic attacks.
5. Instructions for Use: Dosage and Course of Administration
Dosing must be individualized based on indication, formulation, and patient response. Below is a general guideline:
| Indication | Formulation | Initial Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|---|
| Hypertension | Cardizem CD | 180-240 mg once daily | 240-480 mg once daily | Swallow whole; avoid grapefruit |
| Chronic Stable Angina | IR Tablets | 30 mg 3-4 times daily | 180-360 mg daily in divided doses | With or without food |
| Atrial Fibrillation | IV Injection | 0.25 mg/kg over 2 min | 5-15 mg/hr infusion | Monitor ECG and BP continuously |
Common side effects include headache, dizziness, and edema; these often diminish with continued use. Patients should be advised not to crush or chew ER capsules and to report symptoms like severe bradycardia or rash promptly.
6. Contraindications and Drug Interactions Cardizem
Cardizem is contraindicated in patients with sick sinus syndrome, second- or third-degree AV block (without a pacemaker), hypotension, and acute myocardial infarction with pulmonary congestion. It should be used cautiously in heart failure patients due to potential negative inotropy. Significant drug interactions occur with beta-blockers (risk of bradycardia), digoxin (increased levels), simvastatin (elevated myopathy risk), and CYP3A4 inhibitors like clarithromycin, which can raise diltiazem concentrations. Pregnancy category C; use only if benefits outweigh risks. Always assess renal and hepatic function, as impairment may necessitate dose adjustments.
7. Clinical Studies and Evidence Base Cardizem
Robust evidence supports Cardizem’s efficacy. The DAVIT II trial found diltiazem reduced early mortality and reinfarction in non-Q-wave MI patients. In angina, a meta-analysis in JAMA showed a 40-50% reduction in angina attacks. For hypertension, the VALUE trial highlighted its non-inferiority to valsartan in preventing cardiac events. Recent real-world studies confirm these findings, with longitudinal data indicating sustained BP control and reduced hospitalization rates. Physician reviews consistently rate it high for tolerability, though note variability in individual response, emphasizing the need for personalized dosing.
8. Comparing Cardizem with Similar Products and Choosing a Quality Product
Compared to other calcium channel blockers like amlodipine or verapamil, Cardizem offers a middle ground: less peripheral edema than dihydropyridines and lower constipation risk than verapamil. It is often preferred in patients with concomitant arrhythmias. When selecting, consider formulation: ER versions (e.g., Cardizem CD) provide smoother control than generics without consistent release profiles. Look for FDA-approved products and avoid compounded versions without bioavailability data. For cost-sensitive patients, authorized generics are acceptable, but monitor for efficacy consistency.
9. Frequently Asked Questions (FAQ) about Cardizem
What is the recommended course of Cardizem to achieve results?
Therapeutic effects for hypertension or angina are typically seen within 2 weeks, but full benefits may take 4-6 weeks. Long-term use is often necessary for chronic conditions.
Can Cardizem be combined with beta-blockers?
Yes, but with close monitoring for bradycardia or heart block. Start with low doses and titrate gradually.
Is Cardizem safe during pregnancy?
Limited data; use only if clearly needed and under specialist supervision due to potential fetal effects.
How does Cardizem affect exercise tolerance?
It generally improves tolerance in angina by reducing myocardial oxygen demand, but may cause fatigue in some.
What should I do if I miss a dose?
Take it as soon as remembered, unless close to the next dose; never double dose.
10. Conclusion: Validity of Cardizem Use in Clinical Practice
Cardizem remains a validated, effective option for cardiovascular management, supported by extensive clinical evidence and decades of use. Its risk-benefit profile favors most patients, with adherence to guidelines minimizing adverse events. Healthcare providers should individualize therapy, considering comorbidities and potential interactions. For those with hypertension, angina, or arrhythmias, Cardizem offers reliable control and improved quality of life.
I remember when we first started using Cardizem back in the late 90s—we were skeptical about switching from verapamil for our AFib patients. Had this one guy, Robert, 68, with persistent atrial fibrillation and hypertension that wasn’t well-controlled on beta-blockers alone. We started him on Cardizem CD 180 mg daily, and within two weeks his ventricular rate was down from 130s to 80s at rest. But what surprised me was how few side effects he reported compared to previous regimens; just some mild ankle swelling that resolved with slight dose adjustment.
Our team actually disagreed initially about using it as first-line for older patients with conduction issues. I argued for more monitoring, while my partner was all in based on the early trial data. We had a few cases where the hypotension hit harder than expected—one female patient, Linda, 72, had a syncopal episode after her first IV dose in the ER. Turns out we’d overlooked her borderline low baseline BP. Learned to always check lying and standing pressures after that.
The real eye-opener was following Robert over five years. His BP stayed controlled, no hospitalizations for AFib, and he even managed to reduce his diuretic dose. He told me last visit, “This pill lets me garden without feeling like my heart’s racing away from me.” That kind of longitudinal outcome—plus the failed insights from early over-enthusiasm—shaped how I now balance evidence with individual patient factors. Still use Cardizem regularly, but with more nuanced dosing and a healthy respect for those initial hours after initiation.